Quantum Biopharma (NASDAQ:QNTM) Stock Rating Lowered by Wall Street Zen

Quantum Biopharma (NASDAQ:QNTM) was downgraded by research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report issued on Saturday.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Quantum Biopharma in a research report on Monday, December 29th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company has a consensus rating of “Sell”.

Quantum Biopharma Stock Down 1.9%

NASDAQ QNTM opened at $6.18 on Friday. The company has a 50-day moving average price of $8.14 and a 200-day moving average price of $14.20. Quantum Biopharma has a 52 week low of $2.89 and a 52 week high of $38.25. The firm has a market capitalization of $23.61 million, a P/E ratio of -0.57 and a beta of 0.24.

Quantum Biopharma (NASDAQ:QNTM) last posted its quarterly earnings data on Friday, November 7th. The company reported ($1.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($1.05). As a group, equities research analysts anticipate that Quantum Biopharma will post -3.27 EPS for the current year.

Institutional Investors Weigh In On Quantum Biopharma

A hedge fund recently bought a new stake in Quantum Biopharma stock. Steward Partners Investment Advisory LLC bought a new position in Quantum Biopharma Ltd. (NASDAQ:QNTM) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 3,100 shares of the company’s stock, valued at approximately $63,000. Steward Partners Investment Advisory LLC owned about 0.11% of Quantum Biopharma at the end of the most recent quarter. Institutional investors own 1.24% of the company’s stock.

About Quantum Biopharma

Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company’s three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS. The Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial property.